CD8A and neoplasm: Since the suppression of tumor growth by anti-PD-L1 therapy required CD8+ T cells and anti-PD-L1 treatments alone did not change the T cell number within the tumor parenchyma, we speculated that anti-PD-L1 therapy modulates T cell function.